Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch on Dec. 1 in the United States

November 20, 2025 at 08:30 AM EST

Designed to provide real-time glucose readings for an industry-leading 15.5 days*^†, Dexcom G7 15 Day will be available in the U.S. for people over the age of 18 with diabetes beginning on Dec. 1, 2025.
Dexcom G7 15 Day will first be available through durable medical equipment (DME) providers with full retail launch in the coming weeks.
Dexcom CGM continues to be the most covered and reimbursed CGM brand on the market¹.

DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes will launch in the United States on Dec. 1. At initial launch, Dexcom G7 15 Day will be available for users who receive their Dexcom CGM through DME providers. G7 15 Day will also be covered for Medicare beneficiaries and has met the category requirements for therapeutic CGM systems set forth by the U.S. Centers for Medicare & Medicaid Services. For people between the ages 2 to 18, Dexcom G7 remains the most accurate² continuous glucose monitoring system available.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251120288721/en/

Designed to provide real-time glucose readings for an industry-leading 15.5 days, Dexcom G7 15 Day will be available in the U.S. for people over the age of 18 with diabetes beginning on Dec. 1, 2025.

"We’ve heard loud and clear from our users—they want more time with the Dexcom G7 because it gives them confidence, clarity, and control over their health,” said Grant Ovzinsky, Vice President of Product Management at Dexcom. “With 15.5 days* of wear, we’re delivering on that ask. Fewer sensor changes mean less disruption, and more time benefiting from the most accurate CGM. It’s a meaningful step forward in empowering people with diabetes to live life on their terms.”

With an overall MARD of 8.0%,³ Dexcom G7 15 Day builds on the performance of Dexcom CGM, which is clinically proven to lower A1C, reduce hyper- and hypoglycemia, and increase time in range.^4-7 Available first through DME, the upcoming launch of Dexcom G7 15 Day is a significant advancement in glucose management for people with diabetes, especially those with Medicare coverage.

New with Dexcom G7 15 Day:

Longest lasting^*,†,1CGM system with 15.5 days of wear.^*
Best-in-class accuracy¹with an overall MARD of 8.0%.^1,3
Easier glucose management with fewer monthly sensor changes and reduced monthly waste.

Dexcom G7 features included with Dexcom G7 15 Day:

The only waterproof^§CGM available, keeping you more connected.
Manage diabetes, hands-free. Connect your sensor directly to your Apple Watch^|| so you can leave your iPhone^¶ behind and still see your glucose numbers.
Automated activity logging,^#simplified meal logging, and new medication logging^#help you better understand how activity, food, and medications impact your glucose in real time.
12-hour grace period to replace finished sensors for a more seamless transition between sessions.
Innovative and simple mobile app with Dexcom Clarity integration to easily view glucose patterns, trends and statistics via a range of interactive reports.^**,††
Ability to remotely share glucose numbers with caregivers and loved ones for added support and peace of mind.^‡‡,9
Enhanced and customizable alert settings for improved discretion.

“As a disabled veteran living with Type 2 diabetes, becoming a grandfather has given me a powerful new reason to take charge of my health,” said David Padilla, a Dexcom Warrior. “The new Dexcom G7 15 Day CGM System is going to give me, and so many others like me, more time to focus on what really matters while diabetes takes a backseat.”

At launch, Dexcom G7 15 Day will connect with the iLet Bionic Pancreas and Omnipod^® 5^§§. We are working closely with Tandem and look forward to extending the launch to their customers shortly as they finalize integration. For specific information on pump compatibility and availability with the Dexcom G7 15 Day system, visit Dexcom.com/connectedpumps

To learn more about Dexcom G7 15 Day visit Dexcom.com/15day. Visit Dexcom.com/start to get started with Dexcom G7 today.

About Dexcom

Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.

Dexcom. Discover what you’re made of. For more information, visit www.dexcom.com.

Category: IR

*A study was conducted to assess the sensor life where 73.9% of sensors lasted the full 15 days. When using the product per package labeling, approximately 26% of sensors may not last for the full 15 days. ^†Excludes implantable CGM systems. ^‡Compared to a prior generation Dexcom CGM System. ^§The Dexcom G7 Sensor is water-resistant and may be submerged under eight feet of water for up to 24 hours without failure when properly installed. ^||Compatible smartphone is required to pair a new Dexcom G7 sensor with a compatible Apple Watch. To use Share/Follow the smartphone must be within 33 feet of the Dexcom G7. ^¶Smart device sold separately. To view a list of compatible devices, visit dexcom.com/compatibility. ^#Automated activity and medication logging available in Dexcom G7 app only. **Healthcare providers can register for Dexcom Clarity at clarity.dexcom.com/professional/registration. ^††An internet connection is required for patients to send their glucose data to Dexcom Clarity via a compatible smart device: dexcom.com/compatibility. Healthcare providers will only be able to view a patient’s glucose data if the patient elects to share it with them through Dexcom Clarity. ^‡‡Separate Dexcom Follow app and internet connection required. Users should always confirm readings on the Dexcom G7 app or receiver before making treatment decisions. ^§§The Omnipod 5 Automated Insulin Delivery System is indicated for use by individuals with type 1 diabetes mellitus in persons 2 years of age and older and type 2 diabetes mellitus in persons 18 years of age and older. Dexcom, Dexcom Clarity, Dexcom Follow, Dexcom One, Dexcom Share, Stelo, and any related logos and design marks are either registered trademarks or trademarks of Dexcom, Inc. in the United States and/or other countries.

1 Dexcom, Data on File, 2025. 2 Dexcom, Data on File, 2023. 3 Garg SK, et al. Diabetes Technol Ther. 2025;27(6):413-502 4 Beck RW, et al. JAMA. 2017;317(4):371-378. 5 Beck RW, et al. Ann Intern Med. 2017;167(6):365-374. 6 Martens T, et al. JAMA. 2021;325(22):2262-2272. 7. Welsh JB, et al. J Diabetes Sci Technol. 2024;18(1):143-7. 9 Polonsky WH, et al. Diabetes Technol Ther. 2021;23(3):195-202.